Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases

Recent advances in cell based therapies for lung diseases and critical illnesses offer significant promise. Despite encouraging preclinical results, the translation of efficacy to the clinical settings have not been successful. One of the possible reasons for this is the lack of understanding of the...

Full description

Bibliographic Details
Main Authors: Sara Rolandsson Enes, Anna D. Krasnodembskaya, Karen English, Claudia C. Dos Santos, Daniel J. Weiss
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.647652/full
id doaj-7828fdba5d4745f290d468c57393026f
record_format Article
spelling doaj-7828fdba5d4745f290d468c57393026f2021-04-19T04:27:35ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-04-011210.3389/fphar.2021.647652647652Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung DiseasesSara Rolandsson Enes0Anna D. Krasnodembskaya1Karen English2Claudia C. Dos Santos3Daniel J. Weiss4Department of Experimental Medical Science, Faculty of Medicine, Lund University, Lund, SwedenWellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry, and Biomedical Sciences, Queens University, Belfast, United KingdomCellular Immunology Laboratory, Biology Department, Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, IrelandInterdepartmental Division of Critical Care, Department of Medicine and the Keenan Center for Biomedical Research, St. Michael’s Hospital, University of Toronto, Toronto, ON, CanadaDepartment of Medicine, 226 Health Science Research Facility, Larner College of Medicine, University of Vermont, Burlington, VT, United StatesRecent advances in cell based therapies for lung diseases and critical illnesses offer significant promise. Despite encouraging preclinical results, the translation of efficacy to the clinical settings have not been successful. One of the possible reasons for this is the lack of understanding of the complex interaction between mesenchymal stromal cells (MSCs) and the host environment. Other challenges for MSC cell therapies include cell sources, dosing, disease target, donor variability, and cell product manufacturing. Here we provide an overview on advances and current issues with a focus on MSC-based cell therapies for inflammatory acute respiratory distress syndrome varieties and other inflammatory lung diseases.https://www.frontiersin.org/articles/10.3389/fphar.2021.647652/fullcell therapymesenchymal stromal cells (MSCs)mscslung diseasesrespiratory diseases and disorders
collection DOAJ
language English
format Article
sources DOAJ
author Sara Rolandsson Enes
Anna D. Krasnodembskaya
Karen English
Claudia C. Dos Santos
Daniel J. Weiss
spellingShingle Sara Rolandsson Enes
Anna D. Krasnodembskaya
Karen English
Claudia C. Dos Santos
Daniel J. Weiss
Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases
Frontiers in Pharmacology
cell therapy
mesenchymal stromal cells (MSCs)
mscs
lung diseases
respiratory diseases and disorders
author_facet Sara Rolandsson Enes
Anna D. Krasnodembskaya
Karen English
Claudia C. Dos Santos
Daniel J. Weiss
author_sort Sara Rolandsson Enes
title Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases
title_short Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases
title_full Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases
title_fullStr Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases
title_full_unstemmed Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases
title_sort research progress on strategies that can enhance the therapeutic benefits of mesenchymal stromal cells in respiratory diseases with a specific focus on acute respiratory distress syndrome and other inflammatory lung diseases
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2021-04-01
description Recent advances in cell based therapies for lung diseases and critical illnesses offer significant promise. Despite encouraging preclinical results, the translation of efficacy to the clinical settings have not been successful. One of the possible reasons for this is the lack of understanding of the complex interaction between mesenchymal stromal cells (MSCs) and the host environment. Other challenges for MSC cell therapies include cell sources, dosing, disease target, donor variability, and cell product manufacturing. Here we provide an overview on advances and current issues with a focus on MSC-based cell therapies for inflammatory acute respiratory distress syndrome varieties and other inflammatory lung diseases.
topic cell therapy
mesenchymal stromal cells (MSCs)
mscs
lung diseases
respiratory diseases and disorders
url https://www.frontiersin.org/articles/10.3389/fphar.2021.647652/full
work_keys_str_mv AT sararolandssonenes researchprogressonstrategiesthatcanenhancethetherapeuticbenefitsofmesenchymalstromalcellsinrespiratorydiseaseswithaspecificfocusonacuterespiratorydistresssyndromeandotherinflammatorylungdiseases
AT annadkrasnodembskaya researchprogressonstrategiesthatcanenhancethetherapeuticbenefitsofmesenchymalstromalcellsinrespiratorydiseaseswithaspecificfocusonacuterespiratorydistresssyndromeandotherinflammatorylungdiseases
AT karenenglish researchprogressonstrategiesthatcanenhancethetherapeuticbenefitsofmesenchymalstromalcellsinrespiratorydiseaseswithaspecificfocusonacuterespiratorydistresssyndromeandotherinflammatorylungdiseases
AT claudiacdossantos researchprogressonstrategiesthatcanenhancethetherapeuticbenefitsofmesenchymalstromalcellsinrespiratorydiseaseswithaspecificfocusonacuterespiratorydistresssyndromeandotherinflammatorylungdiseases
AT danieljweiss researchprogressonstrategiesthatcanenhancethetherapeuticbenefitsofmesenchymalstromalcellsinrespiratorydiseaseswithaspecificfocusonacuterespiratorydistresssyndromeandotherinflammatorylungdiseases
_version_ 1721521547719475200